European Union

Note: The project descriptions reflect the status and objectives of the projects at their initial stage.

S.O.L.A.R.I.S.

Sterile Optimized Lean Automated Robust Integrated Scalable

Project duration: July 2026 – ongoing

Project goal: The S.O.L.A.R.I.S. project aims to advance Advanced Therapy Medicinal Products (ATMPs), such as CAR T cell therapies, by overcoming key limitations in their manufacturing. Despite their transformative clinical benefits, current production processes remain complex, costly, and difficult to scale, resulting in long vein-to-vein times and limited patient access. S.O.L.A.R.I.S. seeks to significantly improve the efficiency, scalability, and accessibility of ATMP manufacturing by advancing the capabilities of the clinically-proven CliniMACS Prodigy® Platform. The project will enable faster, more cost-effective, and more standardized production processes, thereby supporting broader and more equitable access to these life-saving therapies across Europe.

Approach: To achieve these objectives, S.O.L.A.R.I.S will design and validate a series of innovative, digitally enhanced modules to be integrated into the CliniMACS Prodigy® Platform. The new functionalities will be tested across six European ATMP manufacturing hubs representing diverse infrastructures, ranging from established clinical and industrial sites to newly built facilities. This multi-site validation approach will demonstrate rapid technology transfer, improved process robustness, and reduced regulatory and operational risks. In addition, the project integrates sustainability and regulatory considerations by incorporating environmentally friendly, plant-based single-use materials and assessing the impact of the new modules through life-cycle analysis (LCA), while implementing a proactive regulatory strategy with early engagement of relevant authorities. By combining expertise in technology development, clinical application, regulatory frameworks, and sustainability, the S.O.L.A.R.I.S consortium will establish best-practice models for future ATMP manufacturing centers in Europe. The project will not only enhance production efficiency and scalability but also strengthen the competitiveness of the European ATMP sector and contribute to more resilient healthcare systems.

More information: http://www.solaris-atmp.eu/

Identifier: 101286693

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
NetherlandsEindhovenStichting IMEC Nederland
BelgiumLeuvenInteruniversitair Micro-Electronica Centrum
United Kingdom
LondonAutolus Limited
GermanyBerlinCharité – Universitätsmedizin Berlin
SwedenStockholmKarolinska University Hospital Region Stockholm
NetherlandsGroningenUniversity Medical Center Groningen
SpainEsplugues de LlobregatFundacio Privada Per A La Recerca I La Docencia Sant Joan De Deu
EstoniaKambja valdIcosagen Cell Factory Ou
United Kingdom
LondonCell Therapy Catapult Limited
GermanyGiessenGreen Elephant Biotech GmbH
DenmarkAalborg2.-0 Lca Consultants Aps
GermanySt. Ingbertfuture8 gGmbH

LifeLUNG

Improving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapy

Project duration: November 2025 - ongoing

Project goal: Training a network of professionals for tracking and controlling therapeutic immune cells in cancer on immune cell trafficking. The project also aims to train researchers in imaging, bioinformatics, cell engineering and oncology.

Approach: Miltenyi Biotec will develop and track Adaptor CAR T cells via molecular engineering, imaging and bioinformatics, provide R&D platforms, support training/secondments, integrate sustainability, and provide Intellectual Property (IP) for clinical translation.

More information: www.lifelung.eu

Identifier: 101168810

Project coordinator

CountryCityInstitution
BELeuvenKatholieke Universiteit Leuven (KU Leuven) ​

Project partner(s)

CountryCityInstitution
BELeuvenAntleron NV ​
BELeuvenHALO vzw (Associated Partner) ​
BEOostrozebekeHALO, Patiëntenvereniging longtransplantatie UZ Leuven ​
FRSuresnesAssociation Hôpital Foch (HF) ​
FRParis-Saclay ​Université Paris-Saclay (UPS) (Associated Partner) ​
FRGif-sur-Yvette ​Université Paris-Saclay (UPS) ​
ATViennaMedical University of Vienna ​
ATViennaQbD Group Austria GmbH (Associated Partner) ​
DETuebingenEberhard Karls University Tuebingen ​
DEBergisch-Gladbach ​Miltenyi Biotec​
SELundLunds Universitet (LU) ​
SEGothenburg/MölndalAstraZeneca AB (Associated Partner) ​
SEGöteborgXVIVO Perfusion AB ​
ESBarcelonaOmniscope Espana SL ​
ESBarcelonaUniversitat de Barcelona (UB) (Associated Partner) ​
ESBarcelonaUniversitat Internacional de Catalunya (UIC) (Associated Partner) ​
ESBarcelonaFundació HiTT ​
NLUtrechtUniversity Medical Centre Utrecht (UMCU) ​
NLUtrechtUniversiteit Utrecht (UU) ​
NLLeidenStichting Eurotransplant International Foundation (EUT) (Associated Partner) ​
CHBaselUniversity of Basel (UNIBAS) (Associated Partner) ​
UKLondonUniversity College London (UCL) ​
UKCambridgeAstraZeneca AB (Associated Partner) ​
USNew Rochelle, NY ​Mary Ann Liebert, Inc. (Associated Partner) ​
DKAarhusAarhus University ​
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

ERDERA

European Rare Diseases Research Alliance

Project duration: September 2024 – ongoing

Project goal: ERDERA’s overarching goal is to improve the health and well-being of around 30 million people living with a rare disease in Europe by making this region a world-leader in rare-disease (RD) research and innovation.

Approach: ERDERA’s approach is to build a unified European ecosystem that connects research, data, clinical networks, and patient communities to accelerate progress in rare disease diagnosis and treatment. It integrates existing infrastructures, promotes FAIR data sharing, supports clinical trial readiness, funds innovation through public-private partnerships, and ensures patient involvement and capacity building across Europe to translate research into tangible health benefits.

More information: erdera.org

Identifier: 101156595

Project coordinator

CountryCityInstitution
FRParisInstitut National de la Santé et de la Recherche Médicale (INSERM)

Project partner(s): ERDERA Beneficiaries and Participants

T-RAFIC

Training network for tracking and controlling therapeutic immune cells in cancer

Project duration: April 2024 – ongoing

Project goal: The goal of this project is to enhance the understanding of immune cell trafficking under therapeutic influence to improve the efficacy and prioritization of cancer immunotherapies.

Approach: The approach involves combining advanced cell imaging technologies with bioinformatics, cell engineering, and clinical expertise through an interdisciplinary collaboration of academic and industrial partners across Europe. This integration aims to track and visualize immune cells at high resolution in vitro and in vivo, thereby deepening the understanding of immune cell behavior under therapeutic influence in cancer immunotherapies.

Identifier: 101168810

Project coordinator

CountryCityInstitution
DE MunichLudwig-Maximilians-Universitaet Muenchen (LMU)

Project partner(s)

CountryCityInstitution
DKCopenhagenDanmarks Tekniske
NLAmsterdamStichting Vumc
DKHovestadenRegion Hovedstaden
FRParisInstitut Gustave Roussy
UKNottinghamIntelligent Omics Ltd
FRParisInserm
AUInnsbruckMedizinische Universität Innsbruck
ITMilanoHumanitas University
NOOsloOslo Universitetssykehus
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

ARTiDe

Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes

Project duration: July 2023 – ongoing

Project goal: Type 1 diabetes (T1D) is an incurable disease caused by autoimmune destruction of insulin-producing beta cells. The standard of care is insulin replacement, which only addresses the symptoms. The most desirable treatment would be an antigen-specific immunotherapy that controls the disease-driving cells without causing toxicity. Consequently, ARTiDe aims to deliver said immunotherapy through the genetic engineering of patients’ regulatory T cells (Tregs) to express an autoreactive T cell receptor (TCR) that targets a T1D relevant autoantigen.

Approach: The ARTiDe consortium combines the required expertise to set-up a GMP-compliant autoreactive Treg manufacturing process. To reach its goal, ARTiDe will: 1) identify an optimal TCR among autoreactive Tregs to produce TCR-engineered Tregs; 2) develop a novel humanized model of T1D for the pre-clinical evaluation of human TCR-engineered Tregs; 3) assess two innovative approaches to support therapeutic Tregs in vivo; 4) establish a validated GMP-compliant manufacturing process for antigen receptor-engineered human Tregs, including unique processing steps optimizing efficacy and safety; and, 5) deliver an investigational medicinal product dossier (IMPD), an investigator brochure, a pediatric investigation plan, and the clinical study protocol to initiate a subsequent phase I clinical trial.

More information: www.cordis.europa.eu

Identifier:101080823

Project coordinator

CountryCityInstitution
FRParisInstitut National de la Santé et de la Recherche Médicale (INSERM)

Project partner(s)

CountryCityInstitution
FRParisInstitut Curie
PLGdańskPOLTREG SPOLKA AKCYJNA
DEBerlinTechnische Universität Berlin
FRParis​ILTOO Pharma
FRParisInserm Transfert SA
FRParisAssistance publique –Hôpitaux de Paris
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

T-Fitness

Fine-tuning cell networks of exhaustion by synthetic sensors

Project duration: September 2022 – ongoing

Project goal: The T-FITNESS mission is to develop curative T cell immunotherapies for the treatment of solid tumors. A major barrier to successful T cell therapies for solid tumors is T cell exhaustion, which occurs when T cells become fatigued during protracted battles with tumor cells and are no longer able to function properly and fight tumor cells efficiently. To overcome this challenge, the consortium’s vision is to generate antitumor T cells refractory to terminal differentiation and dysfunction by developing microRNA-based synthetic circuits capable of rewiring the transcriptional programs driving T cell exhaustion.

Approach: The consortium’s approach is to 1) identify microRNAs and transcription factors orchestrating T cell exhaustion; 2) develop microRNA-based synthetic logic circuits to fine-tune the expression levels of master regulators governing T cell exhaustion; 3) develop a CRISPR/Cas platform for efficient insertion of T-FITNESS synthetic sensors into genome targeted regions; 4) functionally evaluate T cells reprogrammed with T-FITNESS; and, 5) develop a cGMP-compliant manufacturing process for the clinical translation of T-FITNESS technology.

More information
www.cordis.europa.eu
www.t-fitness-horizon.eu

Identifier: GA101070740

Project coordinator

CountryCityInstitution
DERegensburgStiftung Regensburger Centrum für Interventionelle Immunologie

Project partner(s)

CountryCityInstitution
ESBarcelonaConsorci Institut d’Investigacions Biomediques August Pi i Sunyer
FRParisCentre National de la Recherche Scientifique (CNRS)
ITGenuaFondazione Instituto Italiano di Tecnologia
CHZurichEidesgenössische Technische Hochschule Zürich
ITRomeInnovation Acta S.r.l.
SILjubljanaNational Institute of Chemistry
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

FAIR CHARM

Fast infrared coherent harmonic microscopy

Project duration: January 2022 – June 2026

Project goal: The emergence of innovative research avenues in biomedicine in the last decades (cell therapy, cancer immunotherapy, bionanotechnology) has led to many proof-of-principle demonstrations fostering the hope for new therapeutic strategies for diseases. However, the translation from a laboratory bench into clinical practice has often proven unproductive. One of the reasons for this failure in translation is in the absence of imaging instruments capable of encompassing both the subcellular length-scale, where pathogenic disorders are set in, and that of tissues with differentiated cell types required to organize spatial and temporal functionality. An instrument enabling translation should allow resolving three-dimensional features within this large spatial range and operating with the same physical observables at each length scale, also enabling millisecond temporal resolution to monitor relevant processes. These requirements are essential to elucidate the hierarchical and temporal connections between micro and macro structures and events.

Approach: FAIR CHARM aims at bringing this technique to its full capacity by i) providing access to millimeter imaging depths by building a microscope (SWIM) with excitation in the Short-Wave Infrared Region relying on new laser sources, optimized optics, and ad hoc labelling probes; ii) enabling unprecedented acquisition frame-rates (kHz/s) by the Spectro-temporal Laser Imaging by Diffracted Excitation (SLIDE) approach; iii) adapting Deep Learning recognition algorithms to multiphoton observables. The consortium features photonics innovators, worldwide renown enterprises in laser technology and microscopy, and clinical and biomedical end-users selected within the oncology/immunology, regenerative medicine, and neural signaling fields to provide the scientific push and timely feedback during the development of the final devices: SWIM and SLIDE.

More information: www.unige.ch

Identifier: 101016457

Project coordinator

CountryCityInstitution
CHGenevaUniversity of Geneva

Project partner(s)

CountryCityInstitution
DELübeckUniversität zu Lübeck
HUSzegediSzegedi Biologiai Kutatokozpont
LTVilniusLight Conversion
DELübeckMedizinisches Laserzentrum
DEGöttingenMax-Planck-Gesellschaft für Multidisziplinäre Naturwissenschaften
FRNantesInstitut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement
BELeuvenKatholieke Universiteit Leuven
DEBielefeldLaVision BioTec (integrated into Miltenyi Biotec since 09/2023)

T2Evolve

Accelerating development and improving access to CAR and TCR-engineered T cell therapy in Europe

Project duration: January 2021 – December 2025 (T2EVOLVE e.V. afterwards)

Project goal: The objective of the T2EVOLVE consortium is to accelerate the development of CAR- and TCR-engineered T cell therapies and increase EU cancer patients’ awareness of and access to immunotherapy. This will be accomplished by creating an innovation ecosystem that promotes the development of engineered T cells, thereby increasing patient access to safe and effective T-cell therapies. It will also provide guidance on integrating T cell therapies into the EU health care system in a sustainable way and secure a leading role for Europe in this emerging field.

Approach: The T2Evolve consortium is a highly interactive multi-disciplinary and multi-stakeholder public-private partnership. It delivers novel tools for education to improve communication between healthcare providers and patients. As a part of this project, optimized laboratory models to assess the safety and efficacy of engineered T cells will be provided. Standardized analytical methods for immunomonitoring as well as for quality control and in-process control during the manufacturing process will be also defined. Finally, integration of patient stakeholders will serve to ensure that all activities are focused on patients’ perspectives and needs.

More information: www.t2evolve.com

Identifier: GA 945393

Project coordinator

CountryCityInstitution
DEWürzburgUniversitätsklinikum Würzburg

Project partner(s)

CountryCityInstitution
ITMilanUniversità Vita-Salute San Raffaele
NLAmsterdamAcademisch Medisch Centrum Amsterdam
FRBolognaInstitut National du Cancer GIP (INCA)
FRParisInstitut National de la Santé et de la Recherche Médicale (INSERM)
DELangenBundesinstitut für Impfstoffe und biomedizinische Arzneimittel (PEI)
ITRomeBambino Gesù Paediatric Hospital
ATViennaMedical University of Vienna
ESBarcelonaHospital Clinic Barcelona, Consorci Institut d’Investigaciony Biomediques August Pi i Sunyer (IDIBAPS)
DEMunichFraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V
DEMunichTU München
DEWürzburgT-CURX GmbH
BEBrusselsEuropean Cancer Patient Coalition (ECPC)
BEMaasmechelenBioSci Consulting
ESPamplonaNavarra University Clinic (UNAV)
NLRotterdamErasmus School of Health Policy & Management (ESHPM)
ESBarcelonaHospital de la Santa Creu I Sant Pau
LULuxembourgIT for Translational Medicine
DELeverkusenBayer AG
BEBeerseJanssen Pharmaceutica NV
FRCourbevoieInstitut de Recherches Internationales Servier
CHZurichTakeda Pharmaceuticals International AG
NLThe HaagEuropean Hematology Association (EHA)
NLLeidenAstellas Pharma Europe BV
UKLondonUniversity College London
CHCouvetCelgene International II SARL
DEMunichPatvocates
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

REAP

Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomography

Project duration: January 2021 – June 2025

Project goal: The overall objective of REAP is to reveal the drug tolerant persister (DTP) cells in breast cancer both in vitro and in vivo in a mouse model using contrast enhanced multimodal optical imaging. According to the WHO, breast cancer is the most common cancer both in the developed and less developed world. From the Cancer Country Profiles 2020, the incidence rate of breast cancer is leading all other cancers in European countries at around 13% [1]. Despite the increasing awareness of this disease and the efforts in early diagnosis and screening, it is still the second leading cause of cancer related death in women. In most cases, the culprit for treatment failure of breast cancer is the DTP cells, which survive the treatments and eventually take their toll on patients. Thus far, no available methods can reveal the whereabouts of DTP cells effectively, making the investigation of these cells extremely challenging for cancer researchers.

Approach: REAP proposes a complete imaging toolbox using multimodal two-photon laser scanning optical coherence photoacoustic microscopy (2PLS-OC-PAM) and optical coherence photoacoustic tomography (OC-PAT) to reveal DTP cells in a preclinical setting at multiple scales. The major technological developments in REAP involves contrast agent development, laser development, detector development, and system integration. Breast cancer organoids will be used as the starting point. Contrast agent will then be developed targeting the cancer cells. The contrast agent labeled organoids can be directly studied in the 2PLS-OC-PAM system, or be transplanted to mice, which will be imaged in vivo in the OC-PAT systems. Both longitudinal monitoring of tumor development and image-guided biopsy can be performed using the in vivo imaging systems. The biopsied tissue can be finally evaluated in the 2PLS-OC-PAM system.

More information: www.projectreap.eu

Identifier: GA 101016964

Project coordinator

CountryCityInstitution
ATViennaMedical University of Vienna

Project partner(s)

CountryCityInstitution
ATViennaAIT Austrian Insitute of Technology GmbH
ESSantiago de CompostelaUniversidade de Santiago de Compostela
FITamperePicophotonics Oy
FITampereTampere University
ITTorinoPolitecnico di Torino
DEMunichInnoLas Laser GmbH
NLEnschedeLioniX International
DEBielefeldLaVision BioTec (integrated into Miltenyi Biotec since 09/2023)

NSC-Reconstruct

Novel strategies for cell-based neural reconstruction

Project duration: January 2020 – December 2024

Project goal: Brain damage caused by neuro-impairment and neurodegenerative disorders is highly prevalent and on the rise world-wide. The brain has limited regenerative capacity, and the few available treatment options only focus on the symptoms. The most promising therapeutic concepts for treating brain damage are based on stem cell technologies and cellular reprogramming. To address this gap in treatment options, the NSC-Reconstruct consortium is focusing on the development of a new regenerative approach to combat brain damage that incorporates cell-based repair and anatomical and functional circuit reconstruction using stem cell derived neurons and reprogrammed cells. They also aim to promote the translation and commercialization of new cell and gene products, research tools, and therapies for clinical trials and market approval.

Approach: The NSC-Reconstruct consortium will design high-quality brain repair strategies using cutting-edge technologies and develop specific cellular products, cell reprogramming methods, and research tools. To achieve the project’s goals, the academic team’s expertise in the relevant biological fields, technologies, and models, will be combined with the commercial partners’ experience in translational research and development of products for the market.

More information
www.cordis.europa.eu
www.nsc-reconstruct.com

Identifier: GA 874758

Project coordinator

CountryCityInstitution
ITMilanUniversita degli studi di Milano

Project partner(s)

CountryCityInstitution
ITTurinUniversita degli studi di Torino
DKCopenhagenCopenhagen University
DKBagsvaerdNovo Nordisk
SEStockholmKarolinska Institute
UKCardiffCardiff University
DEMunichHelmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
DEBonnLife and Brain
SELundLund University
DEBonnUniversitätsklinikum Bonn
DEGentVIB VZW
UKCambridgeCambridge University
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

ENDONANO

Quantitative detection of bacterial endotoxin by novel nanotechnological approaches

Project duration: January 2019 – June 2023

Project goal: The scientific and technological goals of ENDONANO included: 1) investigating the capacity of endotoxins to specifically induce inflammatory reactions in human primary blood cells; 2) developing new methods based on endotoxin capture by metal nanoparticles in complex matrices (biological fluids, emulsions, gels, etc.); 3) designing and implementing signal generation and detection methods to quantitatively measure endotoxins in nanoparticle formulations; and, 4) planning assay prototypes to be developed and validated for commercial purposes.

Approach: By merging the beneficiaries’ expertise in immunology, nanotechnology, and physics with a broad approach that addressed toxicology, safety, and related regulatory issues, the ENDONANO network aimed to deliver industry-oriented PhD training of young scientists in the area of safety regulations for drugs and medical devices. In particular, ENDONANO aimed to develop new concepts and methods for the unbiased, quantitative evaluation of bacterial endotoxins in complex matrices, and lay the groundwork for developing new commercially exploitable assays thereof.

More information: www.cordis.europa.eu

Identifier: GA 812661

Project coordinator

CountryCityInstitution
ITRomeConsiglio Nazionale delle Ricerche

Project partner(s)

CountryCityInstitution
ATSalzburgParios Lodron Universität Salzburg
ESBarcelonaFundacio Institut Català de Nanociència i Nanotecnologia
HUBudapestDiagnosticum Gyarto es Forgalmazo Zrt.
DKCopenhagenBluSense Diagnostics
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

EUROoC

Interdisciplinary training network for advancing organ-on-a-chip technology in Europe

Project duration: December 2018 – May 2023

Project goal: The main objective of the EUROoC was to support innovative research projects targeting the development of advanced organ-on-a-chip systems with higher physiological significance that went beyond the culture of monolayers on inert membranes and directly integrated endpoint analysis.

Approach: EUROoC focused on three main aspects: implementing innovative research projects aimed at industrial translation, training early career researchers to develop and utilize this technology, and creating a network of organ-on-a-chip researchers.

More information
www.eurooc.eu
www.cordis.europa.eu

Identifier: GA 812954

Project coordinator

CountryCityInstitution
DETübingenNatural and Medical Science Institute at the University of Tübingen (NMI)

Project partner(s)

CountryCityInstitution
DEJenaUniversitätsklinikum Jena
ATGrazTechnische Universität Graz
CHBernUniversität Bern
SEUppsalaUppsala Universitet
NLEnschedeUniversiteit Twente
NLLeidenAcademisch Ziekenhuis Leiden
LULuxembourgUniversité du Luxembourg
CHLausanneÉcole Polytechnique Fédérale de Lausanne
DEBerlinBundesinstitut für Risikobewertung
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

MATURE-NK

Manufacturing of tumor-reactive natural killer cells

Project duration: June 2018 – November 2022

Project Goal: The Mature NK project was a Marie Sklodowska-Curie Innovative Training Network. It provided future-oriented translational research training for 13 MD/PhD students and was designed to bridge the gap between basic research and applied development of new cell-based therapeutics. It focused on generating knowledge and developing technologies to exploit anti-tumor reactivity of NK cells and aimed to develop anti-cancer immunotherapies based on NK cells.

Approach: The consortium brought together basic and clinical research groups and industrial biotech partners. A student exchange facilitated training in all three sectors. The training was expanded through summer/winter schools focusing on immunotechnology, business management, and intellectual property rights. To improve and amplify the anti-tumor reactivity of the NK cells, the cells were selected and specifically modified, and NK receptor/ligand interactions were modulated.

More information
www.mature-nk.eu
www.cordis.europa.eu

Identifier: GA 765104

Project coordinator

CountryCityInstitution
DEHannoverHannover Medical School

Project partner(s)

CountryCityInstitution
NOOsloUniversity Hospital Oslo
CHBaselUniversity Basel
ITGenoaUniversity Hospital Genoa
FRParisInstitut Pasteur
DEHeidelbergUniversity Heidelberg – Faculty Mannheim
ESBarcelonaUniversitat Pompeu Fabra
ILJerusalemHebrew University Jerusalem
ATViennaMedical University of Vienna
FRMarseilleInnate Pharma SA
NLOssGlycostem Therapeutics BV
DEMunichFraunhofer-Institut für Zelltherapie und Immologie
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

TRACE

Transfer of multivirus-specific T cells following transplantation

Project duration: January 2018 – March 2024

Project goal: A rare but frequently fatal indication after allogenic stem cell transplantation (SCT) in immunocompromised individuals is a refractory viral infection due to deficient T cell response. Adoptive transfer of multivirus-specific T cells is one potential solution for restoring protective T cell immunity. As this method has not yet become standard treatment, the overall objective of the TRACE consortium is to bring it into clinical routine as a lifesaving, curative, and safe way to treat rare but life-threatening viral infections post SCT. For this reason, a multi-national phase III clinical trial to prove its efficacy and safety in immunocompromised individuals will be performed.

Approach: The consortium includes qualified, expert partners from basic, clinical, and industrial research and GMP facilities. To overcome regulatory and structural hurdles, TRACE will provide standardized GMP-procedures, data, ethical and regulatory approvals, and a logistics infrastructure. These efforts will facilitate the development of individualized medicine and, through the trial, show for the first time that individualized immunotherapy can be brought into evidence-based clinical routine for rare diseases.

More information: www.cordis.europa.eu

Identifier: GA 755005

Project coordinator

CountryCityInstitution
DEMunichLudwig-Maximilians-Universität München

Project partner(s)

CountryCityInstitution
ITRomeOspedale Pediatrico Bambino Gesù
NLLeidenAcademisch Ziekenhuis Leiden
FRNancyCentre Hospitalier Régional Universitaire de Nancy
UKNewcastleNewcastle University
BEGentUniversiteit Gent
UKManchesterOrion Clinical Services Ltd.
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

SCIDNET

Developing genetic medicines for severe combined immunodeficiency

Project duration: January 2016 – December 2019

Project goal: Severe combined immunodeficiency (SCID) is classified as a rare disease according to EU criteria (EC regulation no. 141/2000). This project addressed the need to develop innovative treatments, such as gene therapy, from early clinical trials through to a licensed medicinal product , in keeping with the ambitions of the International Rare Diseases Research Consortium (IRDiRC).

Approach: SCIDNET was associated with the lead program, ADA SCID, which had Orphan Drug Designation in the EU. Engagement with the European Medicines Agency (EMA) assisted in the design of the clinical trial. The ADA SCID trial has become a paradigm for the development of technologies and processes that will allow gene therapy for SCID and other bone marrow disorders to become authorized genetic medicines in the future.

More information: www.cordis.europa.eu

Identifier: GA 666908

Project coordinator

CountryCityInstitution
UKLondonUniversity College London

Project partner(s)

CountryCityInstitution
NLLeidenAcademisch Ziekenhuis Leiden
FRParisInstitut National de la Santé et de la Récherche Médical (INSERM)
DEHeidelbergProtaGene GmbH
ITRomeOpsedale San Raffaele S.r.l.
DEFreiburgUniversitätsklinikum Freiburg
FRÉvryAssociation Genethon
DEHannoverMedizinische Hochschule Hannover
UKLondonGreat Ormond Street Hospital for Children NHS Foundation Trust
CHVaudoisCentre Hospitalier Universitaire Vaudois
UKDownderryInternational Patient Organisation for Primary Immunodeficiencies
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

CARAT

Chimeric antigen receptors for advanced therapies

Project duration: January 2016 – December 2019

Project goal: CARAT was an EU-funded collaborative research project involving eight partners from four different European countries (France, Germany, Italy, and the United Kingdom). The consortium’s goal was to develop an efficient and safe technology platform for advanced cellular therapies, namely for manufacturing CAR T cell products for the personalized treatment of cancer patients. The CARAT technology platform enables the automated, safe, and cost-efficient manufacturing of more effective CAR-modified T cells. Thus, the CARAT project spread the clinical use of CAR T cell technologies and supported the goal of serving patients with incurable hematologic malignancies and solid tumors – everywhere in Europe.

Approach: The CARAT consortium simplified the manufacturing process for CAR T cells by implementing automation, thus facilitating more cost-effective CAR T cell manufacturing and scalability of CAR therapies.

More information
www.carat-horizon2020.eu
www.cordis.europa.eu

Identifier: GA 667980

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
ITMilanOspedale San Raffaele S.r.l.
DEBonnBundesinstitut für Impfstoffe und biomedizinische Arzneimittel
FRParisInstitut National de la Santé et de la Recherche Médicale (INSERM)
UKLondonUniversity College London
UKCardiffTrakCel Ltd.
DEFreiburgUniversittsklinikum Freiburg
DESt. IngbertEURICE – European Research and Project Office GmbH

DEEPINSIGHT

Preclinical micro-endoscopy in tumors: Targeting metastatic intravasation and resistance

Project duration: December 2014 – November 2019

Project goal: Poor prognosis of cancer results from two central progression events, (i) the intravasation of cancer cells into blood vessels which leads to metastasis to distant organs and ultimately lethal tumor overload and (ii) cancer cell survival and adaptation to metabolic stress which causes resistance to anti-cancer therapy and limits life expectancy. Using a novel multiphoton microendoscope device, the project aimed to overcome tissue penetration limits and identify important progression events deeply inside tumors. The hard- and software of the microendoscope was optimized for automated position control and panoramic rotation to sample large tissue volumes and validated for stability and safety. We then addressed the locations and mechanisms inside tumors that: (1) enabled tumor-cell migration and penetration into blood vessels for distant metastasis and (2) mediated enhanced tumor-cell survival and resistance to experimental radiation- and chemotherapy. This basic inventory served to address (3) whether and how the niches for both intravasation and resistance overlap and connected with microenvironmental triggers, including defective blood vessels, signalling pathways of malnutrition and hypoxia, and tissue damage.

Approach: The strategies included 3D microscopy of live fluorescent multi-color tumors and molecular reporters to record cancer cell migration, proliferation and death in the context with embedding tissue structures and metabolic signals. Once identified and characterized, (4) the niches and signals inducing intravasation and resistance were exploited as targets to enhance experimental radiation and chemotherapy. Preclinical microendoscopy delivered new insight into cancer progression further contribute impulses to microendoscopy for disease monitoring in patients (“optical biopsy”).

More information: www.cordis.europa.eu

Project coordinator

CountryCityInstitution
NLNijmegenStichting Radboud Universiteit

Project partner(s)

CountryCityInstitution
DEJenaGrintech GmbH
DEBielefeldLaVision BioTec (now Miltenyi Biotec B.V. & Co. KG)

Partner with us

Are you looking for a reliable partner for your next grant project?

Get in touch with our Grant Management Team to discuss your ideas.

You have previously chosen International as your location.
What do you want to do?